{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T01:46:46Z","timestamp":1782870406498,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Henan Provincial Health and Health Commission Joint Construction Project of China","award":["LHGJ20240570"],"award-info":[{"award-number":["LHGJ20240570"]}]},{"name":"Zhengzhou Medical Research Project","award":["ZZYK2024084"],"award-info":[{"award-number":["ZZYK2024084"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05022-z","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T18:22:47Z","timestamp":1778178167000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of primary gastrointestinal diffuse large B cell lymphoma in the rituximab era"],"prefix":"10.1007","volume":"17","author":[{"given":"Luyao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaodong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RuoJin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongjian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"5","key":"5022_CR1","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679\u201390.","journal-title":"Nat Med."},{"issue":"6","key":"5022_CR2","first-page":"393","volume":"60","author":"CR Flowers","year":"2010","unstructured":"Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin. 2010;60(6):393\u2013408.","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"5022_CR3","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1093\/annonc\/mdn525","volume":"19","author":"A Psyrri","year":"2008","unstructured":"Psyrri A, Papageorgiou S, Economopoulos T. Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and management. Ann Oncol. 2008;19(12):1992\u20139.","journal-title":"Ann Oncol"},{"key":"5022_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102443","volume":"110","author":"S Poletto","year":"2022","unstructured":"Poletto S, Novo M, Paruzzo L, Frascione P, Vitolo U. Treatment strategies for patients with diffuse large B-cell lymphoma. Cancer Treat Rev. 2022;110:102443.","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"5022_CR5","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1182\/blood.2021013998","volume":"139","author":"EA Hawkes","year":"2022","unstructured":"Hawkes EA, Barraclough A, Sehn LH. Limited-stage diffuse large B-cell lymphoma. Blood. 2022;139(6):822\u201334. 2022-02-10.","journal-title":"Blood"},{"issue":"2","key":"5022_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105\u201316.","journal-title":"Lancet Oncol."},{"issue":"4","key":"5022_CR7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235\u201342.","journal-title":"N Engl J Med."},{"issue":"7","key":"5022_CR8","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1093\/annonc\/mdh261","volume":"15","author":"S Wohrer","year":"2004","unstructured":"Wohrer S, Puspok A, Drach J, Hejna M, Chott A, Raderer M. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma. Ann Oncol. 2004;15(7):1086\u201390.","journal-title":"Ann Oncol"},{"issue":"2","key":"5022_CR9","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3892\/etm.2011.387","volume":"3","author":"Y Kobayashi","year":"2012","unstructured":"Kobayashi Y, Hatta Y, Hojo A, et al. Long-term follow-up of localized, primary gastric diffuse large B-cell lymphoma treated with rituximab and CHOP. Exp Ther Med. 2012;3(2):304\u20138.","journal-title":"Exp Ther Med."},{"issue":"10","key":"5022_CR10","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","volume":"34","author":"G Salles","year":"2017","unstructured":"Salles G, Barrett M, Foa R, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34(10):2232\u201373.","journal-title":"Adv Ther"},{"key":"5022_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00163","volume":"8","author":"TM Pierpont","year":"2018","unstructured":"Pierpont TM, Limper CB, Richards KL. Past, present, and future of Rituximab-the world\u2019s first oncology monoclonal antibody therapy. Front Oncol. 2018;8:163.","journal-title":"Front Oncol"},{"issue":"3","key":"5022_CR12","first-page":"148","volume":"35","author":"E Dotan","year":"2010","unstructured":"Dotan E, Aggarwal C, Smith MR. Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin\u2019s Lymphoma. P T. 2010;35(3):148\u201357.","journal-title":"P T."},{"issue":"6","key":"5022_CR13","first-page":"837","volume":"123","author":"Z Zhou","year":"2014","unstructured":"Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 2014-02-06. 2014;123(6):837\u201342.","journal-title":"Blood 2014-02-06"},{"issue":"12","key":"5022_CR14","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte. Blood. 2010;116(12):2040\u20135. 2010-09-23.","journal-title":"Blood"},{"issue":"4","key":"5022_CR15","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1365-2141.2012.09177.x","volume":"158","author":"L Lee","year":"2012","unstructured":"Lee L, Crump M, Khor S, et al. Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis. Br J Haematol. 2012;158(4):481\u20138.","journal-title":"Br J Haematol."},{"issue":"1","key":"5022_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1200\/JCO.2002.20.1.197","volume":"20","author":"TN Shenkier","year":"2002","unstructured":"Shenkier TN, Voss N, Fairey R, et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol. 2002;20(1):197\u2013204.","journal-title":"J Clin Oncol."},{"issue":"2","key":"5022_CR17","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/bjh.19470","volume":"205","author":"CS Lewis","year":"2024","unstructured":"Lewis CS, Joy G, Jensen P, et al. Primary gastric diffuse large B-cell lymphoma: A multicentre retrospective study. Br J Haematol. 2024;205(2):534\u201341.","journal-title":"Br J Haematol."},{"issue":"1","key":"5022_CR18","doi-asserted-by":"publisher","first-page":"2198898","DOI":"10.1080\/16078454.2023.2198898","volume":"28","author":"M Ma'Koseh","year":"2023","unstructured":"Ma\u2019Koseh M, Farfoura H, Abufara A, et al. Outcome and patterns of relapse in primary gastric diffuse large B cell lymphoma treated with RCHOP. Hematology. 2023;28(1):2198898.","journal-title":"Hematology."},{"issue":"24","key":"5022_CR19","first-page":"1945","volume":"98","author":"Y Qin","year":"2018","unstructured":"Qin Y, Liu P, Yang JL, et al. Clinical characteristics and treatment strategies for early-stage primary gastric diffuse large B-cell lymphoma. Zhonghua Yi Xue Za Zhi. 2018;98(24):1945\u20131.","journal-title":"Zhonghua Yi Xue Za Zhi."},{"key":"5022_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109902","volume":"188","author":"X Wang","year":"2023","unstructured":"Wang X, Liu X, Zhong QZ, et al. Decreased lymphoma-related deaths and improved long-term relative survival with radiotherapy for early-stage diffuse large B-cell lymphoma in the rituximab era. Radiother Oncol. 2023;188: 109902.","journal-title":"Radiother Oncol."},{"issue":"2","key":"5022_CR21","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1182\/blood-2017-07-793984","volume":"131","author":"T Lamy","year":"2018","unstructured":"Lamy T, Damaj G, Soubeyran P, et al. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood. 2018;131(2):174\u201381.","journal-title":"Blood."},{"issue":"7","key":"5022_CR22","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1002\/cncr.29113","volume":"121","author":"BS Dabaja","year":"2015","unstructured":"Dabaja BS, Vanderplas AM, Crosby-Thompson AL, et al. Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project. Cancer. 2015;121(7):1032\u20139.","journal-title":"Cancer."},{"issue":"1","key":"5022_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJM199807023390104","volume":"339","author":"TP Miller","year":"1998","unstructured":"Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin\u2019s lymphoma. N Engl J Med. 1998;339(1):21\u20136.","journal-title":"N Engl J Med"},{"issue":"12","key":"5022_CR24","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1056\/NEJMoa042040","volume":"352","author":"F Reyes","year":"2005","unstructured":"Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med. 2005;352(12):1197\u2013205.","journal-title":"N Engl J Med"},{"issue":"15","key":"5022_CR25","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1200\/JCO.2004.06.088","volume":"22","author":"SJ Horning","year":"2004","unstructured":"Horning SJ, Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin\u2019s lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol. 2004;22(15):3032\u20138.","journal-title":"J Clin Oncol"},{"issue":"7","key":"5022_CR26","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1200\/JCO.2006.07.0722","volume":"25","author":"C Bonnet","year":"2007","unstructured":"Bonnet C, Fillet G, Mounier N, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol. 2007;25(7):787\u201392.","journal-title":"J Clin Oncol."},{"issue":"14","key":"5022_CR27","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1001\/archinte.160.14.2101","volume":"160","author":"MR DiMatteo","year":"2000","unstructured":"DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160(14):2101\u20137.","journal-title":"Arch Intern Med"},{"issue":"6","key":"5022_CR28","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s10147-005-0524-7","volume":"10","author":"A Tsunoda","year":"2005","unstructured":"Tsunoda A, Nakao K, Hiratsuka K, Yasuda N, Shibusawa M, Kusano M. Anxiety, depression and quality of life in colorectal cancer patients. Int J Clin Oncol. 2005;10(6):411\u20137.","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"5022_CR29","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/00006842-200005000-00007","volume":"62","author":"JM Turner-Cobb","year":"2000","unstructured":"Turner-Cobb JM, Sephton SE, Koopman C, Blake-Mortimer J, Spiegel D. Social support and salivary cortisol in women with metastatic breast cancer. Psychosom Med. 2000;62(3):337\u201345.","journal-title":"Psychosom Med"},{"issue":"1","key":"5022_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-04537-9","volume":"15","author":"Y Feng","year":"2025","unstructured":"Feng Y, Zheng S, Sun Y, Liu L. Location-specific analysis of clinicopathological characteristics and long-term prognosis of primary gastrointestinal diffuse large B-cell lymphoma. Sci Rep. 2025;15(1):19574.","journal-title":"Sci Rep"},{"issue":"4","key":"5022_CR31","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.leukres.2013.01.002","volume":"37","author":"JJ Castillo","year":"2013","unstructured":"Castillo JJ, Sinclair N, Beltr\u00e1n BE, et al. Similar outcomes in Asian and Western patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Res. 2013;37(4):386\u201391.","journal-title":"Leuk Res."},{"issue":"12","key":"5022_CR32","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.17305\/bb.2025.12697","volume":"25","author":"F Du","year":"2025","unstructured":"Du F, Zhou L, Fang R, et al. Gastrointestinal diffuse large B-cell lymphoma: Clinical characteristics and prognostic analysis from SEER database. Biomol Biomed. 2025;25(12):2666\u201379 2025-07-08.","journal-title":"Biomol Biomed"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05022-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05022-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05022-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T01:01:50Z","timestamp":1782867710000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05022-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5022"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05022-z","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in full compliance with the publication guidelines provided by SEER. The data were obtained from SEER, so the approval of an ethics committee was not needed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and\u00a0consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"954"}}